Literature DB >> 18082228

Central blockade of melanocortin receptors attenuates the metabolic and locomotor responses to peripheral interleukin-1beta administration.

Keith W Whitaker1, Teresa M Reyes.   

Abstract

Loss of appetite and cachexia is an obstacle in the treatment of chronic infection and cancer. Proinflammatory cytokines released from activated immune cells and acting in the central nervous system (CNS) are prime candidates for mediating these metabolic changes, potentially affecting both energy intake as well as energy expenditure. The effect of intravenous administration of two proinflammatory cytokines, interleukin (IL)-1beta (15 microg/kg) and tumor necrosis factor (TNF)-alpha (10 microg/kg), on food and water intake, locomotor activity, oxygen consumption (VO2), and respiratory exchange ratio (RER) was evaluated. The two cytokines elicited a comparable decrease in food intake and activated similar numbers of cells in the paraventricular nucleus of the hypothalamus (PVH), a region that plays a critical role in the regulation of appetite and metabolism (determined via expression of the immediate early gene, c-fos). However, only IL-1beta reduced locomotion and RER, and increased VO2, while TNF-alpha was without effect. To examine the role of the melanocortins in mediating IL-1beta- induced metabolic changes, animals were pretreated centrally with a melanocortin receptor antagonist, HS014. Pretreatment with HS014 blocked the effect of IL-1beta on food intake and RER at later time points (beyond 8 h post injection), as well as the hypoactivity and increased metabolic rate. Further, HS014 blocked the induction of Fos-ir in the PVH. These data highlight the importance of the melanocortin system, particularly within the PVH, in mediating a broad range of metabolic responses to IL-1beta.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18082228      PMCID: PMC2323450          DOI: 10.1016/j.neuropharm.2007.10.014

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  42 in total

1.  Decreased fat mass in interleukin-1 receptor antagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure.

Authors:  Emmanuel Somm; Elvire Henrichot; Agnès Pernin; Cristiana E Juge-Aubry; Patrick Muzzin; Jean-Michel Dayer; Martin J H Nicklin; Christoph A Meier
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

2.  Targeted disruption of the melanocortin-4 receptor results in obesity in mice.

Authors:  D Huszar; C A Lynch; V Fairchild-Huntress; J H Dunmore; Q Fang; L R Berkemeier; W Gu; R A Kesterson; B A Boston; R D Cone; F J Smith; L A Campfield; P Burn; F Lee
Journal:  Cell       Date:  1997-01-10       Impact factor: 41.582

3.  Melanin-concentrating hormone: a functional melanocortin antagonist in the hypothalamus.

Authors:  D S Ludwig; K G Mountjoy; J B Tatro; J A Gillette; R C Frederich; J S Flier; E Maratos-Flier
Journal:  Am J Physiol       Date:  1998-04

4.  Time-dependent sensitization of corticotropin-releasing hormone, arginine vasopressin and c-fos immunoreactivity within the mouse brain in response to tumor necrosis factor-alpha.

Authors:  S Hayley; W Staines; Z Merali; H Anisman
Journal:  Neuroscience       Date:  2001       Impact factor: 3.590

5.  A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons.

Authors:  A Ericsson; K J Kovács; P E Sawchenko
Journal:  J Neurosci       Date:  1994-02       Impact factor: 6.167

6.  Role of IL-6 and TNF in thermoregulation and survival during sepsis in mice.

Authors:  L R Leon; A A White; M J Kluger
Journal:  Am J Physiol       Date:  1998-07

7.  Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain.

Authors:  K G Mountjoy; M T Mortrud; M J Low; R B Simerly; R D Cone
Journal:  Mol Endocrinol       Date:  1994-10

8.  Type 1 interleukin-1 receptor in the rat brain: distribution, regulation, and relationship to sites of IL-1-induced cellular activation.

Authors:  A Ericsson; C Liu; R P Hart; P E Sawchenko
Journal:  J Comp Neurol       Date:  1995-10-30       Impact factor: 3.215

9.  Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group.

Authors:  W D Dewys; C Begg; P T Lavin; P R Band; J M Bennett; J R Bertino; M H Cohen; H O Douglass; P F Engstrom; E Z Ezdinli; J Horton; G J Johnson; C G Moertel; M M Oken; C Perlia; C Rosenbaum; M N Silverstein; R T Skeel; R W Sponzo; D C Tormey
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

10.  Simultaneous analysis of the time course for changes in core body temperature, activity, and nociception following systemic administration of interleukin-1beta in the rat.

Authors:  Michael M Morgan; Cecilea C Clayton; Mary M Heinricher
Journal:  Brain Res       Date:  2004-01-23       Impact factor: 3.252

View more
  5 in total

Review 1.  Update on melanocortin interventions for cachexia: progress toward clinical application.

Authors:  Mark Daniel DeBoer
Journal:  Nutrition       Date:  2009-12-08       Impact factor: 4.008

2.  Pathophysiology and treatment of inflammatory anorexia in chronic disease.

Authors:  Theodore P Braun; Daniel L Marks
Journal:  J Cachexia Sarcopenia Muscle       Date:  2010-12-17       Impact factor: 12.910

3.  Cancer cachexia: mechanisms and clinical implications.

Authors:  Claire L Donohoe; Aoife M Ryan; John V Reynolds
Journal:  Gastroenterol Res Pract       Date:  2011-06-13       Impact factor: 2.260

4.  Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic-pituitary-adrenal axis.

Authors:  Theodore P Braun; Xinxia Zhu; Marek Szumowski; Gregory D Scott; Aaron J Grossberg; Peter R Levasseur; Kathryn Graham; Sheehan Khan; Sambasivarao Damaraju; William F Colmers; Vickie E Baracos; Daniel L Marks
Journal:  J Exp Med       Date:  2011-11-14       Impact factor: 14.307

5.  L-arginine abolishes the hypothalamic serotonergic activation induced by central interleukin-1β administration to normal rats.

Authors:  Anderson Iuras; Mônica M Telles; Iracema S Andrade; Gianni M S Santos; Lila M Oyama; Cláudia M O Nascimento; Vera L F Silveira; Eliane B Ribeiro
Journal:  J Neuroinflammation       Date:  2013-12-07       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.